Cannabis Law Report

MARCH 2, 2020

The UK government has eased import restrictions on medicinal cannabis, but has admitted it needs to do much more to improve access for patients. The new measures will be implemented by the Home Office and the Medicines and Healthcare products Regulatory Agency (MHRA) from March 2.

Medicine 59

Medicine Research and Development Clinical Trials Patients 59

TheAnswerPage

FEBRUARY 23, 2022

Some clinical studies have evaluated the safety and efficacy of cannabinoid-based medicines for the treatment of autism spectrum disorder (ASD). What are the common adverse events noted in clinical trials examining the efficacy of cannabinoids for ASD? Fletcher S.

Clinical Trials 52

Clinical Trials Events Therapy Sleep 52

MMJ Recs

APRIL 1, 2024

CBD, one of the many cannabinoids found in the cannabis plant, has been garnering attention for its promising effects on various health conditions. Furthermore, ongoing clinical trials are investigating CBD’s efficacy in treating conditions such as multiple sclerosis, Parkinson’s disease, and substance abuse disorders.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Cannabis Law Report

NOVEMBER 24, 2019

Cannabis-based medicinal products. Making decisions using NICE guidelines explains how we use words to show the strength (or certainty) of our recommendations, and has information about prescribing medicines (including off-label use), professional guidelines, standards and laws (including on consent and mental capacity), and safeguarding.

Medicine 59

Medicine Chronic Pain Research and Development Treatment 59

The Cannigma

FEBRUARY 2, 2021

We also lack information about the extent to which the PD community is informed about medicinal cannabis and whether they have tried cannabis and, if so, with what result.”. More than 8 percent of those surveyed also reported already using cannabinoids, with 54 percent noting a beneficial clinical effect.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

Veriheal

APRIL 11, 2022

The final goal is to introduce medicinal cannabis products to the pharmaceutical drug market. Groff North America is proud to be producing research-grade marijuana, so we can continue growing the field of cannabis-based medicine,” reads an official statement from the company’s website. This means that U.S.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Cannabis Law Report

FEBRUARY 15, 2019

Mr Shanmugam said this just before a joint statement by the Home Affairs and Health ministries which set out the government’s position the use of pharmaceutical products containing cannabinoids. On the other hand, they found that are some medicine with cannabinoid products that are scientifically researched and medically approved.

Medicine 45

Medicine Pharmaceutical Law Cannabinoids 45

Cannabis Law Report

JANUARY 24, 2022

Accomplished leader to oversee Goldfinch Bio’s clinical function to advance precision medicines for people living with kidney disease. Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. CAMBRIDGE, Mass.–(BUSINESS

Clinical Trials 52

Clinical Trials Research and Development Data Medicine 52

Cannabis Law Report

OCTOBER 15, 2021

At Kidney Week 2021, Goldfinch Bio will present multiple e-posters, including: The design of TRACTION-2, the ongoing Phase 2 clinical trial evaluating GFB-887 for the treatment of focal segmental glomerulosclerosis (FSGS) and diabetic nephropathy (DN). CAMBRIDGE, Mass.–(BUSINESS Poster Number: INFO37. Goldfinch Bio, Inc.

Clinical Trials 52

Clinical Trials Research and Development Data Patients 52

The Joint Blog

JANUARY 23, 2020

The study is titled “Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review.” ” “Medicinal cannabis has received increased research attention over recent years due to loosening global regulatory changes”, states the study’s abstract.

Clinical Trials 52

Clinical Trials Sleep Marijuana Cannabinoids 52

Cannabis Law Report

JANUARY 19, 2022

With his extensive experience in Congress and as a policy advisor on topics including health, technology, and education, we are confident Congressman Moran will be a great asset to IGC especially at a time when we pursue Phase 2/3 human trials on IGC- AD1 on individuals that have Alzheimer’s disease. www.igcinc.us , www.igcpharma.com.

Clinical Trials 52

Clinical Trials Research and Development Education Therapy 52

Medicinal Marijuana Association

FEBRUARY 11, 2024

The anti-inflammatory properties of certain cannabinoids in cannabis could also play a role in protecting retinal cells from damage associated with the condition. Studies have shown that cannabinoids, the active compounds in cannabis, may help decrease intraocular pressure by facilitating better fluid drainage from the eye.

Treatment 52

Treatment Blood Pressure Conditions Clinical Trials 52

TheAnswerPage

JANUARY 11, 2022

As reviewed in a recent Forbes article, “a study of more than 400 health care professionals has revealed that most physicians lack knowledge of medicinal cannabis, with 65% saying that they have been asked about medical marijuana as a treatment for chronic pain but were unable to answer their patients’ questions” (1).

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

SEPTEMBER 20, 2021

Opticann medical cannabis products merge cannabis medicine with modern medicine. The products leverage pharmaceutical technology to maximize performance and safety. CB4 products are formulated based on the latest medical evidence and come in convenient dosage forms that deliver effective levels of cannabinoids.

Clinical Trials 52

Clinical Trials Pharmaceutical Data Patients 52

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Healer

DECEMBER 17, 2021

The safety profile of CBD has been acknowledged by major health agencies, such as the World Health Organization (WHO), showing that it’s well-tolerated by animals and humans and rarely produces any dangerous side effects. Glaucoma is still the first condition many people think of when they consider cannabis as a medicine. Medicines 6.1

CBD 98

CBD THC Conditions Medicine 98

The Joint Blog

DECEMBER 27, 2020

According to a new study published in the peer-reviewed journal Cannabis and Cannabinoid Research (and also epublished by the National Institute of Health), those with post-traumatic stress disorder who consume marijuana display reduced symptoms over time compared to those who do not use marijuana at all.

Clinical Trials 49

Clinical Trials Marijuana Dispensary Treatment 49

Cannabis Law Report

JUNE 4, 2021

Dr. Titus holds a Fellowship with the American Academy of Pain Management and clinical association with the American Association of Integrative Medicine. We support Delta-8 but feel that it is not the same as CBD or CBG in that these cannabinoids should be treated as dietary supplements (if new Senate legislation passes).

Research and Development 105

Research and Development Seed-To-Sale Cannabinoids THC 105

The Cannigma

AUGUST 26, 2021

The country legalized medical cannabis in 2016, but patients in the country have long criticized the program as too restrictive, and access to cannabis-based medicines remains behind that of many other legal cannabis jurisdictions. This also means that the TGA has not accessed these medicines for their safety, quality, or effectiveness.

Legalization 52

Legalization Access Medicine Clinical Trials 52

Cannabis Law Report

MAY 29, 2022

In May 2021, a Nature Medicine study showed the benefits of MDMA in relieving post-traumatic stress disorder. [4] 4] In April 2021, a separate study from the New England Journal of Medicine demonstrated the efficacy of psilocybin in reducing symptoms of depression. [5] Clinical Trials and Human Subject Protections.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Veriheal

AUGUST 31, 2020

These students showed knowledge and passion for the future of cannabis and posed revolutionary ideas rooted in their training across business, agriculture, biochemistry, public health, pharmacology, medicine, and liberal arts. . Essay: “Integrating Research and Medicine: Cannabis Related Treatment for Neurodegenerative Diseases”.

Research and Development 117

Research and Development Education Agriculture Patients 117

Cannabis Law Report

JUNE 10, 2021

The Traffic Safety Culture Index is an annual survey with national scope and multiple measures relevant to driving after marijuana use. Because THC presence is an imperfect proxy for impairment [ 10 ], driving data may be limited in clarifying what traffic safety risks, if any, are associated with permissive marijuana policies.

Policy 59

Policy Safety Marijuana Data 59

The Cannigma

JULY 1, 2022

Because of this variability in the plant, and because of a lack of standard methods–like chemical analyses of cannabinoids or terpenes–has led to inconsistent scientific results. This is because these types of studies control the most variables to ensure that the results that come out of the trial are as reliable as possible.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Cannabis Law Report

SEPTEMBER 24, 2019

T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. These treatments can be prescribed only by specialist doctors in a limited number of circumstances where other medicines have failed. Recreational use of cannabis remains illegal.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

The Joint Blog

APRIL 17, 2020

According to a new study in the Journal of Clinic Medicine , the use of Tetrahydrocannabinol (THC) could have adverse drug effects when combined with other medications due to drug-drug interactions. Over the past few decades, there has been an increased interest in leveraging cannabis and cannabinoids for medicinal purpose.

Events 48

Events THC Chronic Pain Sleep 48

The Cannigma

JUNE 15, 2021

Cannabidiol (CBD) belongs to a class of molecules called cannabinoids , which are produced almost exclusively in cannabis — hence the name. The two cannabinoids can also cause very different effects in other ways. CBD is also often compared to CBG (cannabigerol) , another increasingly popular cannabinoid. CBD vs CBDA.

CBD 122

CBD Research and Development Epilepsy Extraction 122

Cannabis Law Report

JULY 4, 2021

Cannabidiol or CBD is one of the most common cannabinoids found in cannabis. Even though CBD is an important component in medicinal cannabis, it is also derived from the hemp plant. Clinical trials across the EU have also shown CBD oils and other hemp products to have a potential range of benefits. What Is CBD?

THC 105

THC CBD Legalization Oil 105

Healer

DECEMBER 17, 2021

The safety profile of CBD has been acknowledged by major health agencies, such as the World Health Organization (WHO), showing that it’s well-tolerated by animals and humans and rarely produces any dangerous side effects. Glaucoma is still the first condition many people think of when they consider cannabis as a medicine. Medicines 6.1

CBD 52

CBD THC Conditions Medicine 52

The Joint Blog

JULY 25, 2020

Out of all the cannabinoids, CBD from hemp is the most widely used for manufacturing cannabis-derived products such as oils, tinctures, candies, and even cosmetics because it carries almost no THC – the compound that gives marijuana its mind-altering properties. CBD Legal and Safety Issues An FDA report presented to the U.S.

CBD 33

CBD Clinical Trials Safety Media 33

Cannabis Law Report

SEPTEMBER 3, 2019

(TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven cannabis extraction, distillation, purification and cannabinoid isolation, is pleased to announce that its subsidiary MediPharm Labs Australia Pty. Gaining Momentum in Australia: Facility Construction Update.

Pharmaceutical 45

Pharmaceutical Extraction Research and Development Supply Chain 45

Kind Meds (Cannabis Education Blog)

JANUARY 9, 2019

GW Pharma carefully developed Epidiolex using cannabinoids to reduce the occurrence of seizures. Thanks to their diligence in perfecting the drug and ensuring its safety for intended use, the Drug Enforcement Agency scheduled Epidiolex under the lowest Schedule classification for controlled substances.

Research and Development 97

Research and Development Treatment Pharmaceutical Conditions 97

Canna Law Blog

APRIL 17, 2020

For example, the US government conducted studies and found that dogs have many cannabinoid receptors in their cerebellum, brain stem, and medulla oblongata. AAFCO members include state agencies, the FDA Center for Veterinary Medicine and the Candian Food Inspection Agency. What’s going on here in Indiana?

Pets 58

Pets Hemp CBD Food 58

SpeedWeed

AUGUST 3, 2021

Over the past several months, onlookers have watched heavily hyped, high-inducing cannabinoids divide the hemp industry. As a growing number of states step in to regulate these controversial substances, such as delta-8 tetrahydrocannabinol (THC), multiple cannabinoids join the fray. Photo courtesy of Ethan Russo Dr. Ethan Russo, M.D.

THC 58

THC Vaping Blood Pressure Hemp 58

SpeedWeed

AUGUST 5, 2021

Over the past several months, onlookers have watched heavily hyped, high-inducing cannabinoids divide the hemp industry. As a growing number of states step in to regulate these controversial substances, such as delta-8 tetrahydrocannabinol (THC), multiple cannabinoids join the fray. Photo courtesy of Ethan Russo Dr. Ethan Russo, M.D.

THC 52

THC Vaping Cannabinoids Blood Pressure 52

SpeedWeed

AUGUST 4, 2021

Over the past several months, onlookers have watched heavily hyped, high-inducing cannabinoids divide the hemp industry. As a growing number of states step in to regulate these controversial substances, such as delta-8 tetrahydrocannabinol (THC), multiple cannabinoids join the fray. Photo courtesy of Ethan Russo Dr. Ethan Russo, M.D.

THC 52

THC Marijuana Vaping Blood Pressure 52

SpeedWeed

AUGUST 4, 2021

Over the past several months, onlookers have watched heavily hyped, high-inducing cannabinoids divide the hemp industry. As a growing number of states step in to regulate these controversial substances, such as delta-8 tetrahydrocannabinol (THC), multiple cannabinoids join the fray. Photo courtesy of Ethan Russo Dr. Ethan Russo, M.D.

THC 52

THC Vaping Blood Pressure Hemp 52

Puff Puff Post

NOVEMBER 5, 2019

. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. For more information, visit www.inmedpharma.com. About INM-755.

Clinical Trials 40

Clinical Trials Pharmaceutical Cannabinoids Data 40